Posts by: Alice Melão

News

Cotinga Pharmaceuticals is seeking approval from the U.S. Food and Drug Administration (FDA) to expand its ongoing Phase 1 trial of COTI-2 to include combination therapies and a broader spectrum of ... Read more

March 5, 2018

FDA Grants Orphan Drug Status to GamaMabs’ GM102 for Treatment of Gynecological Cancers

News

The U.S. Food and Drug Administration granted orphan drug status to GamaMabs Pharma’s investigative therapy GM102 for the treatment of gynecological cancers, including ovarian, fallopian tube, and primary peritoneal cancers. The ... Read more

February 9, 2018

Prexasertib Shrinks Ovarian Cancer Tumors in a Third of Phase 2 Trial Participants

News

The DNA repair inhibitor prexasertib shrank the tumors of a third of the ovarian cancer patients treated with it in a Phase 2 clinical trial, preliminary results show. Its developer, Eli ... Read more

January 29, 2018

Tablet Form of Lynparza Approved in Japan as Maintenance Therapy for Recurrent Ovarian Cancer

News

Japanese women with advanced ovarian cancer can now be treated with the new tablet formulation of Lynparza (olaparib) after a recent approval by the Japanese Ministry of Health, Labour and ... Read more

November 29, 2017

SOTIO Enrolls First Patient in Another Phase 2 Trial of Its Ovarian Cancer Immunotherapy

News

SOTIO has enrolled its first ovarian cancer patient in a Phase 2 clinical trial evaluating its immunotherapy DCVAC/OvCa. The SOV06 trial will look at the therapy’s effectiveness as an add-on to ... Read more

November 27, 2017

First Patients Enroll in Phase 2 Trial of Acelarin as Treatment for Chemo-resistant Ovarian Cancer

News

NuCana has started a Phase 2 clinical trial of its ovarian cancer therapy Acelarin (NUC-1031) by enrolling the first patients in the United States and Britain. It will continue to recruit 64 participants who ... Read more

November 17, 2017November 17, 2017

ARRY-382-Keytruda Combo Shows Positive Results in Ovarian, Other Solid Cancers

News

The combination of Array BioPharma‘s immunotherapy ARRY-382 and Keytruda (pembrolizumab) has a manageable safety profile and has shown preliminary signs of effectiveness in pancreatic and ovarian cancer patients, a new Phase 1b ... Read more

October 23, 2017

Oncbiomune to Advance Ovarian Cancer Vaccine into Clinical Trials

News

OncBioMune Pharmaceuticals is advancing its investigative ovarian cancer vaccine OvcaVax into human clinical trials to test its safety and efficacy in the adjuvant (after surgery) setting. OncBioMune announced it will meet in ... Read more

October 18, 2017

Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors

News

The investigational medicine tinostamustine (EDO-S101), developed by Mundipharma EDO GmbH, is now being tested in patients with advanced solid tumors, including ovarian cancer, in a first-in-human Phase 1/2 clinical trial. ... Read more

October 4, 2017

Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients

News

All ovarian cancer patients treated in the Phase 1b OVATION trial benefited from the combination of Celsion‘s GEN-1 with standard of care. The trial enrolled advanced ovarian cancer patients who ... Read more